Category Archives: Blog

The popularity of the autoimmune track is still in full swing…

Autoimmune diseases are a diverse and complex group of disorders characterized by immune dysregulation resulting from aberrant interactions between the innate and adaptive immune systems. Their pathogenesis is multifactorial, and the clinical manifestations are highly heterogeneous, posing significant challenges to effective treatment. Although recent advances have shed light on key pathological processes and molecular mechanisms,…

1. CAR Positivity Detection As CAR-T therapy matures, reliably measuring CAR expression on T cells has become crucial for preclinical quality control, release criteria, and efficacy prediction. The key metric, “CAR positivity rate” (%CAR⁺), reflects how well CAR binds its target antigen, typically assessed via flow cytometry or ELISA. Common detection reagents include: Notably, detection…

Up to $13 billions! A Roundup of Major Autoimmune Transactions in the First Half of 2025.

Acute myeloid leukemia (AML) is a complex and highly heterogeneous hematologic malignancy closely associated with various cytogenetic and chromosomal abnormalities. Among them, mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are one of the most common genetic alterations. Studies have shown that approximately 25% of AML patients carry FLT3 internal tandem duplication mutations (FLT3-ITD), while about…

Efforts to improve traditional ADCs have primarily focused on the three key components: the antibody, the linker, and the payload. Previously, we summarized the research progress in bispecific ADCs. Here, we further consolidate the pipeline updates of dual-payload ADCs.

At the 2025 AACR Annual Meeting, Chinese ADC drugs have emerged in various forms such as bispecific ADCs and dual-toxin ADCs, forming a unique landscape at the AACR meeting. Here, we summarize the key players and target pipelines in the bispecific ADC (BsADC) space, based on AACR data.